Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.

Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016. by Duncan LR, Smith CJ, Flamm RK and Mendes RE. published in J. Glob. Antimicrob. Resist. 2020; 20: 118-123

Bacterial and fungal pathogens isolated from patients with bloodstream infection: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017).

Bacterial and fungal pathogens isolated from patients with bloodstream infection: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). by Pfaller MA, Carvalhaes CG, Smith CJ, Diekema DJ and Castanheira M. published in Diagn. Microbiol. Infect. Dis. 97 (2): 115016, 2020.

Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019)

Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019). Lead author: MD Huband. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 1019.
Poster #P1143

Evaluation of Tedizolid and Comparators’ Activity Against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections from Paediatric Patients in Europe and Surrounding Countries (2015-2019)

Evaluation of Tedizolid and Comparators’ Activity Against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections from Paediatric Patients in Europe and Surrounding Countries (2015-2019). Lead author: CG Carvalhaes. This poster was originally intended for presentation at the 30th ECCMID (Paris, France; April 18-21, 2020). This meeting was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book (Abstract 2338).
Poster #P1156

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates Collected from US Medical Centers in 2016-2018

Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates Collected from US Medical Centers in 2016-2018. Lead author: HS Sader. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 473.
Poster #P3598

Resistance Mechanisms Associated with Pleuromutilins among Gram-Positive Clinical Isolates from the Worldwide Surveillance Program for Lefamulin in 2018

Resistance Mechanisms Associated with Pleuromutilins among Gram-Positive Clinical Isolates from the Worldwide Surveillance Program for Lefamulin in 2018. Lead author: RE Mendes. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 1322.
Poster #P0962

Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019)

Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019). Lead author: CG Carvalhaes. This poster was originally intended for presentation at the 30th ECCMID (Paris, France; April 18-21, 2020). This meeting was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book (Abstract 2359)
Poster #P1174

In Vitro and In Vivo Activity of Manogepix/Fosmanogepix, a Novel Antifungal with Activity against Aspergillus and Rare Moulds

In Vitro and In Vivo Activity of Manogepix/Fosmanogepix, a Novel Antifungal with Activity against Aspergillus and Rare Moulds. Lead author: MD Huband presented at 9th Advances Against Aspergillosis and Mucormycosis (AAAM) 2020, February 27-29, Lugano, Switzerland
Poster #27

Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018.

Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. by Flamm RK, Duncan LR, Hamed KA, Smart JI, Mendes RE and Pfaller MA. published in Antimicrobial agents and chemotherapy. 2020; 64 (6): e02566

In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.

In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018. by Messer SA, Carvalhaes CG, Castanheira M and Pfaller MA published in Diagn. Microbiol. Infect. Dis., 2020; 97 (1): 115007.